A 58-year-old cancer survivor on no active therapy develops PE. Which initial treatment aligns with guideline preferences?...

Question

A 58-year-old cancer survivor on no active therapy develops PE. Which initial treatment aligns with guideline preferences?

Accepted Answer

DOAC (e.g., apixaban) is an appropriate first-line option

Answer

LMWH only for all cancer patients

Answer

Warfarin preferred over DOACs

Answer

Aspirin monotherapy

Answer

No anticoagulation due to bleeding risk

us-usmle-step-2 MCQ (SBA): Cancer-Associated VTE